ATE365039T1 - 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's - Google Patents
4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer'sInfo
- Publication number
- ATE365039T1 ATE365039T1 AT04726514T AT04726514T ATE365039T1 AT E365039 T1 ATE365039 T1 AT E365039T1 AT 04726514 T AT04726514 T AT 04726514T AT 04726514 T AT04726514 T AT 04726514T AT E365039 T1 ATE365039 T1 AT E365039T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonites
- heterocyclylalkoxy
- histamine
- heterocyclyl
- alzheimer
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229960001340 histamine Drugs 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0308333.4A GB0308333D0 (en) | 2003-04-10 | 2003-04-10 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE365039T1 true ATE365039T1 (de) | 2007-07-15 |
Family
ID=9956580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04726514T ATE365039T1 (de) | 2003-04-10 | 2004-04-08 | 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20060205774A1 (enExample) |
| EP (1) | EP1610786B9 (enExample) |
| JP (1) | JP2006522771A (enExample) |
| KR (1) | KR20050111638A (enExample) |
| CN (1) | CN1805747A (enExample) |
| AR (1) | AR044006A1 (enExample) |
| AT (1) | ATE365039T1 (enExample) |
| AU (1) | AU2004228949B2 (enExample) |
| BR (1) | BRPI0409110A (enExample) |
| CA (1) | CA2521899A1 (enExample) |
| CO (1) | CO5640135A2 (enExample) |
| DE (1) | DE602004007119T2 (enExample) |
| ES (1) | ES2288681T3 (enExample) |
| GB (1) | GB0308333D0 (enExample) |
| IS (1) | IS8118A (enExample) |
| MA (1) | MA27726A1 (enExample) |
| MX (1) | MXPA05010816A (enExample) |
| NO (1) | NO20055256L (enExample) |
| RU (1) | RU2005134006A (enExample) |
| TW (1) | TW200503710A (enExample) |
| WO (1) | WO2004089373A1 (enExample) |
| ZA (1) | ZA200507795B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050256118A1 (en) * | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| EP1892241B1 (en) | 2005-05-30 | 2016-03-30 | Msd K.K. | Novel piperidine derivative |
| ES2371774T3 (es) * | 2005-06-03 | 2012-01-10 | Abbott Laboratories | Derivados de ciclobutilamina. |
| CA2609957A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
| DE602006010870D1 (de) | 2005-06-20 | 2010-01-14 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| GB0514812D0 (en) * | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| WO2007035703A1 (en) | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
| US7943605B2 (en) | 2005-10-27 | 2011-05-17 | Ucb Pharma S.A. | Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses |
| PE20071068A1 (es) | 2005-12-20 | 2007-12-13 | Glaxo Group Ltd | Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3 |
| JP2009521448A (ja) | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| AU2006331850A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Substituted aniline derivatives useful as histamine H3 antagonists |
| EP2502918B1 (en) | 2006-07-25 | 2015-03-25 | Cephalon, Inc. | Pyridazinone Derivatives |
| TW200823204A (en) * | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| KR101108109B1 (ko) * | 2007-01-22 | 2012-02-06 | 화이자 프로덕츠 인코포레이티드 | 치료 화합물의 토실레이트 염 및 이의 약학 조성물 |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| BRPI0914891A2 (pt) * | 2008-06-20 | 2015-11-24 | Metabolex Inc | agonistas de aril gpr119 e usos dos mesmos |
| EP2483281B1 (en) | 2009-10-01 | 2014-06-04 | Cymabay Therapeutics, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| BR112012032248A2 (pt) | 2010-06-23 | 2016-09-13 | Metabolex Inc | composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina |
| BR112014013461A2 (pt) | 2011-12-08 | 2017-06-13 | Taisho Pharmaceutical Co Ltd | derivado de fenilpirrol |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| HUP1300139A2 (en) * | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| JP6426694B2 (ja) | 2013-03-15 | 2018-11-21 | グローバル ブラッド セラピューティクス インコーポレイテッド | ヘモグロビンの修飾のための化合物及びその使用 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CN106715440B (zh) | 2015-04-21 | 2019-02-22 | 江苏恒瑞医药股份有限公司 | 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用 |
| WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| MX2021009685A (es) * | 2019-03-05 | 2021-09-10 | Eisai R&D Man Co Ltd | Compuesto heterociclo pentaciclico. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166853A (en) * | 1978-05-05 | 1979-09-04 | The Upjohn Company | Antihypertensive 7-trifluoromethyl-4-aminoquinolones |
| JPH07509694A (ja) * | 1992-05-14 | 1995-10-26 | ベイラー・カレッジ・オブ・メディシン | 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ |
| US5364791A (en) * | 1992-05-14 | 1994-11-15 | Elisabetta Vegeto | Progesterone receptor having C. terminal hormone binding domain truncations |
| DE4407139A1 (de) * | 1994-03-04 | 1995-09-07 | Thomae Gmbh Dr K | Aryl-1-azacycloalkane und deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
| CA2214288C (en) * | 1996-09-18 | 2006-07-18 | Lonza Ag | Process for the preparation of 1-acyl-4-arylpiperidines |
| EP0837065A1 (de) * | 1996-10-16 | 1998-04-22 | Ciba SC Holding AG | Phenylglycidylether-HALS |
| JP4516717B2 (ja) * | 2000-07-13 | 2010-08-04 | アボット・ラボラトリーズ | ヒスタミン−３受容体リガンドとしての１，３−二置換ピロリジン及び１，３，３−三置換ピロリジン並びにそれらの治療的応用 |
| US6515013B2 (en) * | 2000-07-13 | 2003-02-04 | Abbott Laboratories | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications |
| CA2418369A1 (en) * | 2000-08-08 | 2002-02-14 | Richard Apodaca | Non-imidazole aryloxyalkylamines as h3 receptor ligands |
| CA2439152C (en) * | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| WO2002076440A2 (en) * | 2001-03-23 | 2002-10-03 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease with piperidin derivates |
| US7459461B2 (en) * | 2001-10-19 | 2008-12-02 | Ortho-Mcneil Pharmaceutical, Inc. | Phosphonic acid compounds as inhibitors of serine proteases |
-
2003
- 2003-04-10 GB GBGB0308333.4A patent/GB0308333D0/en not_active Ceased
-
2004
- 2004-04-07 AR ARP040101188A patent/AR044006A1/es not_active Application Discontinuation
- 2004-04-08 AT AT04726514T patent/ATE365039T1/de not_active IP Right Cessation
- 2004-04-08 US US10/551,985 patent/US20060205774A1/en not_active Abandoned
- 2004-04-08 RU RU2005134006/04A patent/RU2005134006A/ru not_active Application Discontinuation
- 2004-04-08 BR BRPI0409110-8A patent/BRPI0409110A/pt not_active Application Discontinuation
- 2004-04-08 ES ES04726514T patent/ES2288681T3/es not_active Expired - Lifetime
- 2004-04-08 MX MXPA05010816A patent/MXPA05010816A/es not_active Application Discontinuation
- 2004-04-08 AU AU2004228949A patent/AU2004228949B2/en not_active Ceased
- 2004-04-08 DE DE602004007119T patent/DE602004007119T2/de not_active Expired - Fee Related
- 2004-04-08 CN CNA2004800161953A patent/CN1805747A/zh active Pending
- 2004-04-08 JP JP2006505136A patent/JP2006522771A/ja active Pending
- 2004-04-08 WO PCT/EP2004/003985 patent/WO2004089373A1/en not_active Ceased
- 2004-04-08 EP EP04726514A patent/EP1610786B9/en not_active Expired - Lifetime
- 2004-04-08 KR KR1020057019137A patent/KR20050111638A/ko not_active Withdrawn
- 2004-04-08 TW TW093109666A patent/TW200503710A/zh unknown
- 2004-04-08 CA CA002521899A patent/CA2521899A1/en not_active Abandoned
-
2005
- 2005-09-27 ZA ZA200507795A patent/ZA200507795B/en unknown
- 2005-10-06 CO CO05101708A patent/CO5640135A2/es not_active Application Discontinuation
- 2005-10-11 MA MA28548A patent/MA27726A1/fr unknown
- 2005-11-08 IS IS8118A patent/IS8118A/is unknown
- 2005-11-09 NO NO20055256A patent/NO20055256L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2521899A1 (en) | 2004-10-21 |
| MXPA05010816A (es) | 2005-12-05 |
| WO2004089373A1 (en) | 2004-10-21 |
| EP1610786B9 (en) | 2008-02-27 |
| BRPI0409110A (pt) | 2006-03-28 |
| CO5640135A2 (es) | 2006-05-31 |
| EP1610786B1 (en) | 2007-06-20 |
| CN1805747A (zh) | 2006-07-19 |
| DE602004007119D1 (de) | 2007-08-02 |
| NO20055256L (no) | 2006-01-10 |
| JP2006522771A (ja) | 2006-10-05 |
| GB0308333D0 (en) | 2003-05-14 |
| ES2288681T3 (es) | 2008-01-16 |
| DE602004007119T2 (de) | 2008-02-21 |
| ZA200507795B (en) | 2006-07-26 |
| KR20050111638A (ko) | 2005-11-25 |
| RU2005134006A (ru) | 2006-04-10 |
| US20060205774A1 (en) | 2006-09-14 |
| NO20055256D0 (no) | 2005-11-09 |
| AR044006A1 (es) | 2005-08-24 |
| TW200503710A (en) | 2005-02-01 |
| EP1610786A1 (en) | 2006-01-04 |
| MA27726A1 (fr) | 2006-01-02 |
| AU2004228949A1 (en) | 2004-10-21 |
| AU2004228949B2 (en) | 2006-11-02 |
| IS8118A (is) | 2005-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004007119D1 (de) | 4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl-carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's | |
| ATE466581T1 (de) | Verbindungen auf pyrimidin-basis als gsk-3-hemmer | |
| ATE504565T1 (de) | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen | |
| ATE410161T1 (de) | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen | |
| NO20064726L (no) | Imidazolforbindelser for behandling av neurodegenerative forstyrrelser | |
| DE60333371D1 (de) | 3-(sulfonamidoethyl)-indol-derivate zur verwendung als glucocorticoid-mimetika bei der behandlung von entzündlichen, allergischen und proliferativen erkrankungen | |
| DE60330895D1 (de) | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen | |
| CY1110742T1 (el) | Αναστολεις ινδαζολης, βενζισοξαζολης, και βενζισοθειαζολης | |
| DE602005022113D1 (de) | Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| DE60231442D1 (de) | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivate und verwandte verbindungen als nociceptin analoge und orl1 liganden zur behandlung von schmerz | |
| NO20063787L (no) | Terapeutiske preparater | |
| ATE451363T1 (de) | 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs | |
| ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| ATE506951T1 (de) | Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| ATE328879T1 (de) | Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| ATE504580T1 (de) | Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit | |
| DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
| EP2077719A4 (en) | PIPERIDINE AND PYRROLIDIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
| BRPI0412438A (pt) | novas amidas aza-heterocìclicas úteis para o tratamento da dor | |
| ATE523199T1 (de) | Pyridazinverbindungen und verfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |